Discussing prostate cancer testing with patients
Berentson-Shaw, J.
New Zealand Medical Journal 122(1290): 139-140
2009
ISSN/ISBN: 1175-8716 PMID: 19319181 Document Number: 633565
Document emailed within 1 workday
Related Documents
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747Helfand, B.T.; Xu, J. 2019: Germline testing for prostate cancer prognosis: implications for active surveillance Canadian Journal of Urology 26(5 Suppl 2: 48-49
De la Taille, A.; Houlgatte, A.; Houdelette, P.; Berlizot, P.; Ramirez, J.; Ricordel, I. 1997: Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients) Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(2): 240-245
O'Dell, K.J.; Volk, R.J.; Cass, A.R.; Spann, S.J. 1999: Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions? Journal of Family Practice 48(9): 682-688
Patel, A.; MacLeod, R.; Masters, J.; Keogh, J. 2014: Falling through the cracks: New Zealand prostate cancer survivors' experiences and views regarding PSA testing New Zealand Medical Journal 127(1400): 106-109
Jeske, D.R.; Linehan, J.A.; Wilson, T.G.; Kawachi, M.H.; Wittig, K.; Lamparska, K.; Amparo, C.; Mejia, R.; Lai, F.; Georganopoulou, D.; Smith, S.S. 2017: Two-stage classifiers that minimize PCA3 and the PSA proteolytic activity testing in the prediction of prostate cancer recurrence after radical prostatectomy Canadian Journal of Urology 24(6): 9089-9097
Stenman, U.H.; Leinonen, J.; Alfthan, H.; Rannikko, S.; Tuhkanen, K.; Alfthan, O. 1991: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer Cancer Research 51(1): 222-226
Ngo, L.S.M.; Yeo, A.; Wong, A.S.C.; Tay, M.Hiang. 2007: Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore Annals of the Academy of Medicine Singapore 36(10): 811-814
Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24
Kolontarev, K.B.; Govorov, A.V.; Osipova, T.A.; Sidorenkov, A.V.; Pushkar, D.Yu. 2015: Value of the -2propsa Index and the Prostate Health Index in Patients with Prostate Cancer: Review of Literature and Data of Russian Prospective Study Urologiia 2015(1): 49-53
Wu, C.T.; Chuang, C.K.; Chou, C.C.; Chu, S.H.; Chen, H.W.; Chen, C.S.; Chiang, Y.J.; Liao, S.K. 2000: The role of free to total prostate-specific antigen ratio for prostate cancer in screening patients with total serum levels between 4 and 20 ng/ml Chang Gung Medical Journal 23(3): 142-148
Sun, S.-C.; Zhao, H.; Liu, R.; Wang, B.-L.; Liu, Y.-Q.; Zhao, Y.; Shi, Z.-D. 2017: Expression of long non-coding RNA H19 in prostate cancer and its effect on the proliferation and glycometabolism of human prostate cancer cells Zhonghua Nan Ke Xue 23(2): 120-124
Grosclaude, P.; Menegoz, F.; Schaffer, P.; Macé Lesec'h, J.; Arveux, P.; Le Mab, G.; Soulié, M.; Villers, A. 1997: Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990 Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(4): 647-654
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Liu, J-he.; Li, H-wei.; Tong, M.; Li, M.; Na, Y-qun. 2004: Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer Zhonghua Yi Xue Za Zhi 84(5): 364-368
Perrin, P.; François, O.; Maquet, J.H.; Bringeon, G.; Duteil, P.; Devonec, M. 1991: Circulating prostate cancer specific antigens in benign hypertrophy and localized cancer of the prostate Presse Medicale 20(28): 1313-1319
Fourcade, R-Olivier.; Richaud, P.; Coloby, P.; Malavaud, B. 2007: Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(4 Suppl. 1): 891-910
Incorvaia, L.; Badalamenti, G.; Rini, G.; Arcara, C.; Fricano, S.; Sferrazza, C.; Di Trapani, D.; Gebbia, N.; Leto, G. 2007: MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone Anticancer Research 27(3b): 1519-1525
Spielman, B.; Verhulst, S. 1996: Discussing organ donations with patients Family Medicine 28(10): 698-701